#AntiHIVDrugsMarketinsight

[straitsresearchblogs]

Anti-HIV Drugs Market: Information by Medication Class (Nucleoside Reverse Transcriptase Inhibitors (NRTIS)), Distribution Channel (Hospital Pharmacies), Region — Forecast till 2029

Globally, the prevalence of HIV has been increasing at a concerning rate, which is subsequently increasing testing procedures for HIV and the development of anti-HIV drugs with high efficacy and potency. The anti-HIV drug market is one of the fastest-growing markets across the globe.

Grab a sample PDF here   https://straitsresearch.com/report/anti-hiv-drugs-market/request-sample

An increasing number of infection transmission through contaminated needles and infected blood is subsequently rising the prevalence of HIV across the globe. Currently, HIV infection is treated using nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs). Some of the prominent drugs available in the market include Truvada, Atripla, Stribild, and Prezista/Prezcobix.

The anti-HIV drugs market was valued at USD 26,883.4 million in 2019 and is expected to grow with a CAGR of 6.2%.

Unavailability of Effective Drugs and High Price of Anti-HIV drugs

In Sub Saharan Africa, the rising prevalence of HIV, unavailability of effective drugs, low income, and the high price of anti-HIV drugs prompt the dire need for affordable anti-HIV drugs in the region. As per the data published by the UNAIDS, globally, around 39.7 million people had HIV, and about 1.7 million people died of HIV in 2018. The disease is highly prevalent in developing and underdeveloped countries due to a lack of adequate prevention measures and treatment facilities. The unmet treatment needs and therapeutics in the Asian and African countries provide lucrative opportunities for market growth. The following table depicts the increasing prevalence of HIV and people receiving anti-HIV therapies globally.

Rapid Development of Effective Anti-HIV Drugs by Prominent Players

Globally, the prominent market players, such as Gilead Sciences IncSciences, Inc., GSK, Merck & Co., Inc., Roche, Boehringer Ingelheim, are performing extensive research to develop new products to address the growing demand for effective drugs. The players are also leveraging innovative technologies such as cell therapy and immunomodulation for new drug development. The launch of such innovative drugs in the market is creating lucrative opportunities for the anti-HIV drug market during the forecast period. The following graph depicts the pipeline for anti-HIV drugs by Gilead Sciences Incsciences Inc.

Government Initiatives to Raise Awareness Regarding Diagnosis and Treatment of HIV

Governments and organizations across the globe are actively working to raise awareness regarding HIV and organizing several campaigns to increase community awareness regarding treatment and care. In the U.S., the federal government launched a five-year initiative in 2010, the National HIV/AIDS Strategy, to control the prevalence of HIV and increase access to anti-HIV therapies. In July 2015, the federal government extended the National HIV/AIDS Strategy until 2020.

In India and Brazil, the governments have launched the National AIDS Control Program and the Brazilian HIV/AIDS Programme, respectively, to increase awareness regarding HIV and its treatment options. Thus, increasing awareness about the diagnosis and treatment of HIV is subsequently surging the adoption of effective treatment options, further driving the market growth. The following figure depicts the global and domestic financial resource mobilization in for HIV treatment.

#AntiHIVDrugsMarket #AntiHIVDrugsMarketshare #AntiHIVDrugsMarketsize #AntiHIVDrugsMarketgrowth #AntiHIVDrugsMarkettrends #AntiHIVDrugsMarkettrend #AntiHIVDrugsMarketresearch #AntiHIVDrugsMarketreport #AntiHIVDrugsMarketresearchreports #AntiHIVDrugsMarketinsight #AntiHIVDrugsMarketrevenue #AntiHIVDrugsMarketapplications #AntiHIVDrugsMarketanalysis